Theravance Biopharma, Inc. (TBPH) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Theravance Biopharma, Inc. (TBPH) Healthcare & Pipeline Overview

Theravance Biopharma, Inc. specializes in the discovery and commercialization of respiratory medicines, leveraging a robust pipeline of innovative therapies, including YUPELRI for COPD and multiple investigational drugs targeting inflammatory diseases.

What Is the Investment Thesis for TBPH?

Theravance Biopharma, Inc. presents a compelling investment thesis driven by its innovative product pipeline and strategic partnerships. The company holds a market capitalization of $874M and a P/E ratio of 7.62, indicating potential undervaluation in the biotechnology sector. Key growth catalysts include the ongoing Phase IIb/III trials of Izencitinib, which targets significant unmet medical needs in rheumatoid arthritis and inflammatory bowel diseases, potentially unlocking a market valued at over $20 billion. Additionally, the successful commercialization of YUPELRI, which has established a foothold in the COPD market, contributes to a robust revenue stream. The company's profit margin of 104.3% and gross margin of 104.1% highlight operational efficiency and the potential for strong cash flow generation. However, investors may want to evaluate risks associated with regulatory approvals and competition within the biotechnology space. Overall, Theravance Biopharma's strategic focus on high-demand therapeutic areas and its solid financial metrics position it well for future growth.

Based on FMP financials and quantitative analysis

TBPH Key Highlights

• Market capitalization of $874M reflects a strong position in the biotechnology sector.
• P/E ratio of 7.62 suggests potential undervaluation compared to industry peers.
• Profit margin of 104.3% indicates exceptional operational efficiency.
• Gross margin of 104.1% highlights strong pricing power and cost management.
• Current workforce of 97 employees supports focused operational execution.

Who Are TBPH's Competitors?

TBPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TBPH's Key Strengths?

• Innovative product pipeline with several investigational therapies.
• Strong financial metrics, including high profit and gross margins.
• Established partnerships with major pharmaceutical companies.
• Expertise in respiratory and inflammatory disease markets.

What Are TBPH's Weaknesses?

• Limited commercialized product portfolio compared to larger competitors.
• Dependence on successful outcomes of ongoing clinical trials.
• Relatively small workforce may limit operational scalability.
• No dividend payments may deter income-focused investors.

What Could Drive TBPH Stock Higher?

• Results from Phase IIb/III trials of Izencitinib expected in Q4 2026, which could significantly impact revenue potential.
• Commercialization efforts for YUPELRI continue, with increasing market penetration in the COPD segment.
• Clinical trial results for Nezulcitinib in COVID-19 patients anticipated in 2026, which may lead to new treatment options.
• Collaboration agreements with Pfizer and Takeda are expected to enhance research capabilities and expedite product development.
• Phase I results for Inhaled ALK5i are expected in late 2026, potentially opening new treatment avenues for idiopathic pulmonary fibrosis.

What Are the Key Risks for TBPH?

• Regulatory approval delays for investigational therapies could hinder market entry and revenue generation.
• Competitive pressures from larger biotechnology firms with established product lines may impact market share.
• Dependence on successful clinical trial outcomes poses a risk to future product commercialization.
• Market volatility may affect funding and investment opportunities in the biotechnology sector.

What Are the Growth Opportunities for TBPH?

• Growth opportunity 1: The global COPD market is projected to reach $20 billion by 2027, driven by an aging population and rising prevalence of respiratory diseases. Theravance's YUPELRI, with its once-daily dosing convenience, positions it favorably against competitors, potentially capturing significant market share as awareness and diagnosis improve.
• Growth opportunity 2: Izencitinib's ongoing Phase IIb/III trials target a combined market for rheumatoid arthritis and inflammatory bowel diseases estimated at over $25 billion. Successful outcomes could lead to rapid commercialization, bolstering revenue and enhancing Theravance's reputation in the inflammatory disease sector.
• Growth opportunity 3: The development of Nezulcitinib for acute lung injury related to COVID-19 represents a timely response to ongoing public health challenges. With a growing focus on respiratory health, this drug could tap into a market with substantial unmet needs, especially in the wake of the pandemic.
• Growth opportunity 4: Theravance's investigational therapies for gastrointestinal motility disorders, including Velusetrag, address a niche but significant market. The global gastrointestinal motility disorder market is expected to grow at a CAGR of 6.3%, providing a lucrative opportunity for new treatments that improve patient outcomes.
• Growth opportunity 5: Collaborations with major pharmaceutical companies like Pfizer and Takeda enhance Theravance's research capabilities and market reach. These partnerships not only provide financial support but also facilitate access to broader distribution networks, accelerating the development and commercialization of its product pipeline.

What Opportunities Does TBPH Have?

• Expanding market for COPD and inflammatory disease treatments.
• Potential for successful commercialization of investigational therapies.
• Increased focus on respiratory health post-COVID-19 pandemic.
• Growing demand for specialized treatments in healthcare.

What Threats Does TBPH Face?

• Intense competition from established biotechnology firms.
• Regulatory challenges and potential delays in drug approvals.
• Market volatility affecting funding and investment in biotech.
• Changes in healthcare policies impacting reimbursement rates.

What Are TBPH's Competitive Advantages?

• Strong product pipeline with multiple investigational therapies addressing significant unmet needs.
• Established relationships with major pharmaceutical companies enhance market access and credibility.
• High profit and gross margins indicate operational efficiency and pricing power.
• Focus on specialized therapeutic areas creates barriers to entry for competitors.
• Robust clinical trial data supporting product efficacy and safety enhances competitive positioning.

What Does TBPH Do?

Theravance Biopharma, Inc. was founded in 2013 and is headquartered in George Town, Cayman Islands. The company emerged from a focus on developing innovative biopharmaceuticals, particularly in the field of respiratory medicine. Its flagship product, YUPELRI, is a once-daily nebulized long-acting muscarinic antagonist approved for the treatment of chronic obstructive pulmonary disease (COPD). Beyond YUPELRI, Theravance's pipeline includes several promising candidates such as Izencitinib, a gut-selective pan-Janus kinase (JAK) inhibitor currently in Phase IIb/III trials for rheumatoid arthritis and inflammatory bowel diseases. The company also explores treatments for neurogenic orthostatic hypotension with Ampreloxetine, a norepinephrine reuptake inhibitor that has completed Phase III studies. Nezulcitinib, a nebulized JAK inhibitor, is in Phase II development for acute lung injury related to COVID-19, showcasing Theravance's commitment to addressing urgent health challenges. Additionally, the company is advancing several investigational therapies targeting idiopathic pulmonary fibrosis and gastrointestinal motility disorders. Theravance Biopharma has established licensing and collaboration agreements with notable pharmaceutical companies, including Pfizer Inc. and Takeda Pharmaceutical Company Limited, enhancing its market reach and development capabilities. With a dedicated workforce of 97 employees, Theravance Biopharma is strategically positioned to capitalize on the growing demand for innovative respiratory and inflammatory disease therapies across the U.S., Europe, and Asia.

What Products and Services Does TBPH Offer?

• Discover and develop innovative respiratory medicines.
• Commercialize YUPELRI for chronic obstructive pulmonary disease (COPD).
• Conduct clinical trials for various investigational therapies targeting inflammatory diseases.
• Engage in licensing and collaboration agreements with major pharmaceutical companies.
• Focus on addressing unmet medical needs in respiratory and gastrointestinal health.
• Leverage a specialized workforce to drive research and development initiatives.

How Does TBPH Make Money?

• Generate revenue through the sale of YUPELRI and other commercialized products.
• Engage in partnerships and collaborations to enhance research capabilities and market access.
• Pursue clinical trials for investigational therapies to secure future revenue streams.
• Capitalize on licensing agreements to expand product offerings and reach.
• Utilize operational efficiency to maintain high profit and gross margins.

What Industry Does TBPH Operate In?

The biotechnology industry is characterized by rapid innovation and significant investment in research and development. With a projected market growth rate of 7.4% annually, reaching approximately $2.4 trillion by 2028, companies like Theravance Biopharma are well-positioned to capitalize on increasing demand for novel therapies. The competitive landscape includes established players and emerging biotech firms, with a focus on specialized treatments for chronic and acute diseases. Theravance's emphasis on respiratory and inflammatory diseases aligns with current healthcare trends prioritizing targeted therapies and personalized medicine.

Who Are TBPH's Key Customers?

• Healthcare providers prescribing respiratory and inflammatory disease treatments.
• Patients suffering from chronic obstructive pulmonary disease (COPD) and other related conditions.
• Pharmaceutical partners involved in collaborative research and development.
• Healthcare institutions and payers seeking innovative treatment solutions.
• Regulatory bodies overseeing drug approvals and market access.

Company Profile

Theravance Biopharma, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Rick E. Winningham. TBPH has traded publicly since 2014.

F-Score 7/9Financial Health

Theravance Biopharma, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.50 places it in the grey zone, a middle ground that warrants monitoring.

ROE 44%Key Financial Metrics

Return on equity for Theravance Biopharma, Inc. stands at 43.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 24.3%, showing how much profit it generates from its asset base. TBPH trades at a trailing price-to-earnings ratio of 7.55, below the Healthcare sector average of ~23x. Its free cash flow yield is 30.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 13.14 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 13.3%, the inverse of the P/E and a quick read on earnings relative to price.

TBPH Valuation & Market Position

With a $874M market cap, Theravance Biopharma, Inc. sits in the small-cap segment of the market. Relative to its peer group, TBPH's quantitative score of 97/100 is roughly in line with the peer average of 94/100.

FY2026 estForward Outlook

Wall Street analysts project Theravance Biopharma, Inc. revenue of about $110.3M for fiscal 2026, with EPS near $2.66.

TBPH Financials

TBPH Latest News

TBPH Analyst Consensus

TBPH MoonshotScore

TBPH Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources